PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Application Number 10/006,290 Filing Date **TRANSMITTAL** October 22, 2001 First Named Inventor **FORM** Jay WOHLGEMUTH Art Unit 1634 (to be used for all correspondence after initial filing) Examiner Name B. L. Sisson

Total Number of	Pages in This Submission	2+10 References	Attorney Docket Number	506612000100
	ENC	CLOSURES	Check all that appl	(y)
X Fee Transn	nittal Form - 2 pages	Drawing(s)		After Allowance Communication to TC
Fee /	Attached	Licensing-rela	ated Papers	Appeal Communication to Board of Appeals and Interferences
Amendmer	Amendment/Reply Petition			Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
After	Final	Petition to Co Provisional A		Proprietary Information
Affida	avits/declaration(s)		rney, Revocation rrespondence Address	Status Letter
Extension of	of Time Request	Terminal Disc	claimer	Other Enclosure(s) (please Identify below):
Express At	pandonment Request	Request for	Refund	 PTO/SB/08a/b - 2 pages 10 References
	Disclosure Statement ntal) - 3 pages	CD, Number of CD(s)		Return Receipt Postcard
Certified Co	opy of Priority	Landso	ape Table on CD	
	issing Parts/	Remarks		
	y to Missing Parts under FR 1.52 or 1.53			
	SIGNATU	RE OF APPLICA	ANT, ATTORNEY, OR	AGENT
Firm Name	MORRISON & FOER	STER LLP (Cu	stomer No. 20872)	
Signature	OPA			
Printed name	Otis Littlefield			
Date	26/06		Reg. No.	48,751
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below. Dated: 2/7/66 Signature: (Victoria A. Wilson)				

PTO/SB/17 (12-04v2)
Approved for use through 7/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no person are required to respond to a collection of information unless it displays a valid OMB control number.

Effective on 12/08/2004.				Complete if Known				
Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).				Application Num	ber	10/006,290		
FEE TRANSMITTAL				Filing Date		October 22, 20	001	
For FY 2005				First Named Inv	entor	Jay WOHLGE	MUTH	
	FULL 1 Z	303		Examiner Name		B. L. Sisson		
X Applican	t claims small entity sta	us. See 37 CFR 1.27		Art Unit		1634		
TOTAL AMOU	NT OF PAYMENT	(\$) 180.00	į	Attomey Docket	No.	506612000100	<u> </u>	
METHOD OF	PAYMENT (check	all that apply)					_	
Check	Credit Card	Money Order	Non	e Other (please iden	tify):	,	
x Deposit Ac	count Deposit Account	Number: <u>03-1952</u> Depo	osit Acco	ount Name:	Mo	rrison & Foers	ter LLP	
For the	above-identified dep	osit account, the Direct	ctor is	hereby authorize	d to: (che	ck all that apply)		
x CI	narge fee(s) indicate	d below		Charge	e fee(s) in	dicated below, e	xcept for th	e filing fee
X Cf	narge any additional e(s) under 37 CFR 1	fee(s) or underpayme 1.16 and 1.17	ent of	x Credit	any overp	ayments		
FEE CALCUL	_ATION	<u> </u>						
1. BASIC FILIN	G, SEARCH, AND E	XAMINATION FEES						
	F	LING FEES	SEA	ARCH FEES	EXAMI	NATION FEES		
Application Ty	/pe Fee (S	Small Entity Fee (\$)	ee (\$)	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	Fees P	aid (\$)
Utility	300	150	500	250	200	100		
Design	200	100	100	50	130	65		
Plant	200	100	300	150	160	80		
Reissue	300	150	500	250	600	300		
Provisional	200	100	0	0 .	0	0		
2. EXCESS CL	AIM FEES							Small Entity
Fee Description							Fee (\$)	Fee (\$)
I .	r 20 (including Reiss	•					50	25
	nt claim over 3 (inc	uding Reissues)					200	100
Multiple depend	dent claims						360	180
Total Claims	Extra Claims	Fee (\$)	Fee F	Paid (\$)	<u>N</u>	lultiple Depende		ì
	- 20 =	× =			<u>F</u>	ee (\$)	Fee Paid (\$,
Indep. Claims	Extra Claims	Fee (\$)	Fee P	Paid (\$)				-
	- 3 =	x =						
3. APPLICATIO								ļ
		xceed 100 sheets of p						,
		the application size f				entity) for each a	ogitional 5	'
sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s). Total Sheets Extra Sheets Number of each additional 50 or fraction thereof Fee (\$) Fee Paid (\$)								
- 100 = /50 (round up to a whole number) x =								
4. OTHER FEE							Fees	Paid (\$)
Non-English	Specification, \$13	0 fee (no small entity	disco	ount)				_
Other (e.g., late filing surcharge): 1806 Submission of an Information Disclosure Statement 180.00								
SUBMITTED BY								
Signature	E)9-A			Registration No. (Attorney/Agent)	48,751	Telephone	(415) 26	8-6846
Name (Print/Type)	Otis Littlefield					Date	February	7, 2006

FEB 102006

Iffereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to:

MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, an the date shown below.

Patent Docket No. 506612000100

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Jay WOHLGEMUTH et al.

Serial No.: 10/006,290

Filing Date: October 22, 2001

For: LEUKOCYTE EXPRESSION

PROFILING

Examiner: B. L. Sisson

Group Art Unit: 1634

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO/SB/08a/b. Copies of the documents are also submitted herewith. The Examiner is requested to make these documents of record.

02/13/2006 BABRAHA1 00000074 031952 10006290

01 FC:1806

180.00 DA

	This Supplemental Information Disclosure Statement is submitted:
	With the application; accordingly, no fee or separate requirements are required.
	Before the mailing of a first Office Action after the filing of a Request for Continued
	Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97
	(e)(1) has been provided.
	Within three months of the application filing date or before mailing of a first Office Action
	on the merits; accordingly, no fee or separate requirements are required. However, if
	applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
\boxtimes	After receipt of a first Office Action on the merits but before mailing of a final Office
	Action or Notice of Allowance.
	A fee is required. A check in the amount of is enclosed.
	A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached
	to this submission in duplicate.
	A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly; no fee is
	believed to be due.
	After mailing of a final Office Action or Notice of Allowance, but before payment of the
	issue fee.
	A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the
	amount of is enclosed.
	A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal
	form (PTO/SB/17 is attached to this submission in duplicate.)
	Applicants would appreciate the Examiner initialing and returning the Form

Applicants would appreciate the Examiner initialing and returning the Form PTO/SB/08a/b, indicating that the information has been considered and made of record herein.

The information contained in this Supplemental Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent and Trademark Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petition and/or other fees due in connection with the filing of this document to Deposit Account No. 03-1952 referencing docket no. 506612000100.

Dated: 2/6/06

Respectfully submitted,

Registration No.: 48,751

MORRISON & FOERSTER LLP

425 Market Street

San Francisco, California 94105-2482

(415) 268-6846

FEB 102006

Substitute for form 1449/PTO

1

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Ξ Γ	Application Number	10/006,290			
	Filing Date	October 22, 2001			
	First Named Inventor	Jay WOHLGEMUTH			
	Art Unit	1634			
	Examiner Name	B. L. Sisson			
	Attorney Docket Number	506612000100			

Complete if Known

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

2

	FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T⁰		
	1.	SG-200302150-8	07-25-2002	Expression Diagnostics, Inc.				

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	2.	Australian Search Report mailed October 7, 2005, for Singapore patent application no. SG 200406287-3, filed April 24, 2003, 2 pages	
	3.	BAKKE, Antony C. et al., (2001) "Neutrophil CD64 expression Distinguishing acute inflammatory autoimmune disease from systemic infections," Clinical and Applied Immunology Reviews, 1: 267-275	
	4.	DEUEL, Thomas F. et al., (June 1977) "Amino acid sequence of human platelet factor 4," Proc. Natl. Acad. Sci. USA, 74(6): 2256-2258	
	5.	DEUEL, Thomas F. et al., (July 1981) "Platelet factor 4 is chemotactic for neutrophils and monocytes," Proc. Natl. Acad. Sci. USA, 78(7): 4584-4587	
	6.	DUDEK, Arkadiusz Z. et al., (June 15, 2003) "Platelet factor 4 promotes adhesion of hematopoietic progenitor cells and binds IL-8: novel mechanisms for modulation of hematopoiesis," Blood, 101(12): 4687-4694	
	7.	GOLDEN-MASON, Lucy et al., (June 2000) "Differential Expression of Lymphoid and Myeloid Markers on Differentiating Hematopoietic Stem Cells in Normal and Tumor-Bearing Adult Human Liver," Hepatology, 31(6): 1251-1256	
	8.	MORRIS, Dale L. et al., (Feb. 1997) "Immunophenotyping Analysis of Peripheral Blood, Splenic, and Thymic Lymphocytes in Male and Female Rats," Journal of Pharmacological and Toxicological Methods,	

Examiner	Date	
Signature	Considered	



Complete if Known Substitute for form 1449/PTO 10/006,290 Application Number **INFORMATION DISCLOSURE** Filing Date October 22, 2001 First Named Inventor Jay WOHLGEMUTH STATEMENT BY APPLICANT 1634 Art Unit (Use as many sheets as necessary) B. L. Sisson Examiner Name 2 506612000100 Sheet Attorney Docket Number

		37: 37-46	
9	€.	SHIN, Young Kee et al., (April 2001) "Expression of Leukemia-	
		Associated antigen, JL1, in Bone Marrow and Thymus," American	
		Journal of Pathology, 158(4): 1473-1480	
1	10.	STELLRECHT, Christine M. et al., (1991) "Expression pattern of a	
		hematopoietic proteoglycan core protein gene during human	
		hematopoiesis," Differentiation, 48: 127-135	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	Date	
Signature	 Considered	

^{&#}x27;Applicant's unique citation designation number (optional). 'Applicant is to place a check mark here if English language Translation is attached.